In the last trading session, 1.95 million Vir Biotechnology Inc (NASDAQ:VIR) shares changed hands as the company’s beta touched 0.54. With the company’s per share price at $10.23 changed hands at -$0.29 or -2.80% during last session, the market valuation stood at $1.41B. VIR’s last price was a discount, traded about -41.25% off its 52-week high of $14.45. The share price had its 52-week low at $6.56, which suggests the last value was 35.87% up since then. When we look at Vir Biotechnology Inc’s average trading volume, we note the 10-day average is 5.73 million shares, with the 3-month average coming to 2.08 million.
Analysts gave the Vir Biotechnology Inc (VIR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.56. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended VIR as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Vir Biotechnology Inc’s EPS for the current quarter is expected to be -0.87.
Vir Biotechnology Inc (NASDAQ:VIR) trade information
Instantly VIR was in red as seen at the end of in last trading. With action 28.62%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 39.31%, with the 5-day performance at 28.62% in the green. However, in the 30-day time frame, Vir Biotechnology Inc (NASDAQ:VIR) is 30.75% up. Looking at the short shares, we see there were 6.55 million shares sold at short interest cover period of 4.51 days.
The consensus price target for the stock as assigned by Wall Street analysts is 24, meaning bulls need an upside of 57.38% from its current market value. According to analyst projections, VIR’s forecast low is 20 with 28 as the target high. To hit the forecast high, the stock’s price needs a -173.7% plunge from its current level, while the stock would need to soar -95.5% for it to hit the projected low.
Vir Biotechnology Inc (VIR) estimates and forecasts
Data shows that the Vir Biotechnology Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 6.84% over the past 6 months, a 14.60% in annual growth rate that is considerably lower than the industry average of 16.70%. Year-over-year growth is forecast to reach -12.77% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 9.37M. 4 analysts are of the opinion that Vir Biotechnology Inc’s revenue for the current quarter will be 13.66M. The company’s revenue for the corresponding quarters a year ago was 16.79M and 56.38M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -44.19%. The estimates for the next quarter sales put growth at -75.77%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -34.12%. The 2025 estimates are for Vir Biotechnology Inc earnings to increase by 15.42%.
VIR Dividends
Vir Biotechnology Inc is expected to release its next quarterly earnings report in February.
Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.90% of Vir Biotechnology Inc shares while 74.11% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.12%. There are 74.11% institutions holding the Vir Biotechnology Inc stock share, with SB INVESTMENT ADVISERS (UK) LTD the top institutional holder. As of 2024-06-30, the company held 12.3329% of the shares, roughly 16.68 million VIR shares worth $148.49 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 12.1482% or 16.43 million shares worth $146.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . With 5.82 shares estimated at $59.51 million under it, the former controlled 4.23% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.51% of the shares, roughly 3.46 shares worth around $35.39 million.
